Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPID | Q08752 | 4/20 | 0.66 |
| ▸ | PPIB | P23284 | 1/20 | 0.66 |
| ▸ | PPIA | P62937 | 1/20 | 0.66 |
| ▸ | PPIG | Q13427 | 1/20 | 0.66 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | TPSAB1 | Q15661 | 5/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7321110 | 0.88 | ALOX15 (0.61) | ALOX15HPGDHTTMEN1GAA | |
| SCHEMBL16205822 | 0.86 | TPSAB1 (0.57) | PPIDPPIBPPIAPPIGHTT | |
| SCHEMBL6824244 | 0.81 | CYP3A4 (0.66) | PPIDPPIBPPIAPPIGALOX15 | |
| SCHEMBL4829258 | 0.81 | MAPT (0.59) | ALOX15HPGDHTTMEN1GAA | |
| SCHEMBL22046135 | 0.81 | PPID (0.59) | PPIDPPIBPPIAPPIGHPGD | |
| SCHEMBL31467556 | 0.80 | PPID (0.66) | PPIDPPIBPPIAPPIGALOX15 | |
| SCHEMBL2044119 | 0.79 | PPID (1.00) | PPIDPPIBPPIAPPIGHTT | |
| SCHEMBL8269677 | 0.78 | HPGD (0.71) | HPGDGAATPSAB1L3MBTL1CYP3A4 | |
| SCHEMBL16205823 | 0.78 | HTT (0.70) | HTTMEN1GAAKMT2ATPSAB1 | |
| SCHEMBL752665 | 0.78 | CYP4F2 (0.72) | PPIDPPIBPPIAPPIGHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287438-A1 | Agent for preventing or treating neuropathy | MOMOSE YU | 2008-11-20 | — | — | US | disclosed |
| US-7423159-B2 | Agent for preventing or treating neuropathy | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-09 | — | — | US | disclosed |
| US-20060004069-A1 | Agent for preventing or treating neuropathy | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1556032-A1 | AGENT FOR PREVENTING OR TREATING NEUROPATHY | Takeda Pharmaceutical Company Limited (JP) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004039365-A1 | AGENT FOR PREVENTING OR TREATING NEUROPATHY | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004069-A1 | Agent for preventing or treating neuropathy | NR2C2, NR0B2, NR2E1 | PPID 4060/4885PPIB 2787/4885PPIA 3978/4885 |
| US-20080287438-A1 | Agent for preventing or treating neuropathy | NR2C2, NR0B2, NR2E1 | PPID 4060/4885PPIB 2787/4885PPIA 3978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.